Unfractionated heparin, low molecular weight heparins, and pentasaccharide: Basic mechanism of actions, pharmacology, and clinical use

Rodger L. Bick, Eugene P. Frenkel, Jeanine Walenga, Jawed Fareed, Deborah A. Hoppensteadt

Research output: Contribution to journalReview article

51 Scopus citations

Abstract

During the past decade, a large number of new anticoagulant and antithrombotic drugs have been developed. These agents represent a wide variety of substances that are derived using natural sources, biotechnology-based methods, and synthetic approaches. Because of the structural and molecular characteristics, these agents exhibit physicochemical and functional diversities. Thus, each of these classes of drugs controls thrombogenesis by way of distinct mechanisms. The main classes of these new drugs include peptides, peptidomimetics, heparinomimetics, and recombinant proteins. Despite these significant developments, heparin and heparin-derived drugs have continued to play a major role in the management of thrombotic and cardiovascular disorders.

Original languageEnglish (US)
Pages (from-to)1-51
Number of pages51
JournalHematology/Oncology Clinics of North America
Volume19
Issue number1
DOIs
StatePublished - Jan 1 2005

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Unfractionated heparin, low molecular weight heparins, and pentasaccharide: Basic mechanism of actions, pharmacology, and clinical use'. Together they form a unique fingerprint.

  • Cite this